Stefano Buono

Stefano Buono (born 1966) is an Italian physicist, and the chief executive officer (CEO) of Advanced Accelerator Applications, a company he founded in 2002 to develop a patent from the European Organization for Nuclear Research (CERN) in the radioisotope production field.[1][2]

Stefano Buono
Buono in 2014
Born1966 (age 56–57)
Avellino, Italy
NationalityItalian
EducationUniversity of Turin, Italy
Known forCEO and founder of Advanced Accelerator Applications (AAA) - NASDAQ: AAAP
Scientific career
FieldsPhysics

Biography

Stefano Buono was born in 1966 in Avellino, Italy. He attended high school in Turin, Italy and received his master's degree in physics from the University of Turin in 1991.[3]

Career as physicist

Prior to founding Advanced Accelerator Applications in 2002, Buono worked as a physicist at the Centre for Advanced Studies, Research and Development or CRS4. During his six years within CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation (Accelerator-Driven Systems). Before joining CRS4 and in parallel to his appointment at CRS4, Buono worked for approximately ten years with physics Nobel laureate Carlo Rubbia at CERN, one of the leading research laboratory for particle physics in the world. During that term, he also actively participated in the development of CERN's Adiabatic Resonance Crossing method.[4]

Advanced Accelerator Applications

In 2002, Buono founded Advanced Accelerator Applications (NASDAQ: AAAP), a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, diagnostic and therapeutic products.[5] AAA traded on the Nasdaq Global Select Market under the ticker “AAAP.” The first day of trading was 11 November 2015. On January 22, 2018, Novartis AG acquired AAA.[6]

Besides being a founder of Advanced Accelerator Applications, Buono is its CEO and a member of its board of directors.[7][8]

He is the author of numerous scientific publications.[9]

References
  1. Nauman Kuraishi. "Board of Directors". Atreuspharma.com. Retrieved 18 December 2014.
  2. "Credits - who are we ?". Whatisnuclearmedicine.com. Retrieved 18 December 2014.
  3. Sviluppo: ITSPlanet S.r.l. "Advanced Accelerator Applications - AAA". Adacap.com. Retrieved 18 December 2014.
  4. "Stefano Buono: Executive Profile & Biography - Businessweek". Businessweek.com. Archived from the original on December 18, 2014. Retrieved 18 December 2014.
  5. "Advanced Accelerator Applications Acquires GE Healthcare’s FDG-PET Radiopharmaceutical Business in Italy", Diagnostic and Interventional cardiology, September 2014
  6. "Novartis completes tender offer for Advanced Accelerator Applications S.A."
  7. "Advanced Accelerator Applications AAA". Biospace. Retrieved 18 December 2014.
  8. "AAA acquires 100% share of UK nuclear medicine company". Molecular Imaging. Retrieved 18 December 2014.
  9. "Publications de Buono au CRS4". Publications.crs4.it. Retrieved 18 December 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.